finance News

Princeton, NJ – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received approximately $865,000, net of transaction costs, in non-dilutive financing via the state...
BEDFORD, Mass. – Stoke Therapeutics, Inc, a new company working to increase gene expression to treat a wide array of diseases caused by genetic insufficiency, announced that it has completed a $40 million Series A financing to support the further advancement of multiple pre-clinical development programs. The Series A round...
CAMBRIDGE, Mass. – Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced a clinical trial collaboration with Roche to evaluate SRF388, Surface’s investigational anti-IL-27 antibody, in combination with Roche’s atezolizumab and bevacizumab in patients with treatment-naïve hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab...
SOUTH SAN FRANCISCO, Calif., March 18, 2021 — Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today reported its financial results for the year ended December 31,...
BETHESDA, Md. – The Cystic Fibrosis Foundation affirmed its support for the PASTEUR Act, a bipartisan proposal that, if passed, will support the development of new antibiotics and promote appropriate use of existing ones. The organization issued the following statement: “New solutions are needed now to bring novel antibiotics into...
SAN FRANCISCO – Today, VeriSIM Life (VeriSIM) announces the launch of its pharmaceutical subsidiary, PulmoSIM Therapeutics (PulmoSIM) with the mission to address the unmet needs in the treatment of rare respiratory diseases, with an immediate emphasis on pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). PulmoSIM is developing breakthrough...
BOSTON & CAMBRIDGE, Mass. –  Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and Obsidian Therapeutics announced today that the two companies have entered into a strategic research collaboration and licensing agreement focused on the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The collaboration leverages Obsidian’s cytoDRiVE®...
Venture capital and angel investors are the lifeline of biotech companies. But what happens when obtaining an orphan drug designation no longer causes your stock price to double or triple in a matter of day, or allow you to do an IPO? Are VCs still interested? CheckOrphan rolled up its...
Corbeil-Essonnes (near Paris), France – Yposkesi, a leading Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapies, today announces the launch of project SKY, the construction of Yposkesi’s second commercial cell and gene therapy facility and new global resource for drug developers of biologics, also called ATMPs...